MedTrace Logo

Phase I Safety Study of Dendritic Cell Vaccine to Treat Patients With Hepatocellular Carcinoma

NCT01974661 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 18

Last updated 2017-09-29

No results posted yet for this study

Summary

The primary objective of this study is to answer the question "Is it possible to inject the COMBIG-DC vaccine in a hepatic tumor without getting unacceptable side effects"?

Conditions

Interventions

BIOLOGICAL

COMBIG-DC (ilixadencel)

Allogenic dendrite-cell based therapeutic vaccine

Sponsors & Collaborators

  • Uppsala University

    collaborator OTHER

  • Mendus

    lead INDUSTRY

Principal Investigators

  • Magnus Rizell, MD, PhD · Sahlgrenska University Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2017-06-28
Completion
2017-06-28

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01974661 on ClinicalTrials.gov